Thus, between the second and fourth quarter of 2006, the reimbursement rate for dactinomycin increased 3, 442 percent.

FORBES: How Margaret Hamburg's FDA Causes Cancer Drug Shortages

To illustrate my point, I encourage you to look at the 2006 reimbursement rate data for dactinomycin (brand name: Cosmegen), a sterile injectable used to treat various forms of cancer.

FORBES: How Margaret Hamburg's FDA Causes Cancer Drug Shortages